Wall Street brokerages expect Endo International PLC (NASDAQ:ENDP) (TSE:ENL) to announce earnings of $0.47 per share for the current fiscal quarter, Zacks Investment Research reports. Six analysts have issued estimates for Endo International’s earnings, with estimates ranging from $0.40 to $0.52. Endo International reported earnings per share of $0.76 during the same quarter last year, which would suggest a negative year-over-year growth rate of 38.2%. The business is scheduled to issue its next earnings report on Wednesday, August 14th.

On average, analysts expect that Endo International will report full year earnings of $2.17 per share for the current year, with EPS estimates ranging from $2.10 to $2.25. For the next year, analysts anticipate that the company will report earnings of $2.41 per share, with EPS estimates ranging from $1.72 to $3.15. Zacks’ earnings per share calculations are an average based on a survey of sell-side research analysts that that provide coverage for Endo International.

Endo International (NASDAQ:ENDP) (TSE:ENL) last announced its earnings results on Thursday, May 9th. The company reported $0.53 earnings per share for the quarter, beating the consensus estimate of $0.42 by $0.11. Endo International had a negative net margin of 18.35% and a negative return on equity of 199.18%. The firm had revenue of $720.00 million during the quarter, compared to the consensus estimate of $692.31 million. During the same quarter in the previous year, the company posted $0.67 EPS. The firm’s revenue for the quarter was up 2.9% on a year-over-year basis.

Several research analysts recently weighed in on ENDP shares. Svb Leerink downgraded shares of Endo International from an “outperform” rating to a “market perform” rating in a research note on Tuesday, March 5th. Zacks Investment Research downgraded shares of Endo International from a “hold” rating to a “strong sell” rating in a research note on Tuesday, April 30th. ValuEngine raised shares of Endo International from a “sell” rating to a “hold” rating in a research note on Monday, February 4th. Piper Jaffray Companies reissued a “hold” rating on shares of Endo International in a research note on Friday, March 1st. Finally, SunTrust Banks started coverage on shares of Endo International in a research note on Tuesday, March 19th. They issued a “buy” rating and a $13.00 target price for the company. Two analysts have rated the stock with a sell rating, thirteen have given a hold rating and six have assigned a buy rating to the company. The stock presently has an average rating of “Hold” and an average target price of $14.88.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. LS Investment Advisors LLC acquired a new stake in shares of Endo International during the 4th quarter valued at approximately $59,000. Neuberger Berman Group LLC acquired a new stake in shares of Endo International during the 3rd quarter valued at approximately $202,000. First Quadrant L P CA acquired a new stake in shares of Endo International during the 4th quarter valued at approximately $92,000. Signition LP acquired a new stake in Endo International in the first quarter worth $139,000. Finally, Factorial Partners LLC acquired a new stake in Endo International in the first quarter worth $193,000. 90.95% of the stock is owned by institutional investors.

ENDP stock traded down $0.15 during trading on Friday, hitting $5.97. The stock had a trading volume of 29,817 shares, compared to its average volume of 3,280,272. Endo International has a 1-year low of $5.96 and a 1-year high of $18.50. The company has a market capitalization of $1.45 billion, a price-to-earnings ratio of 2.07 and a beta of 1.12.

Endo International Company Profile

Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals.

Recommended Story: Understanding Specialty Certificates of Deposit

Get a free copy of the Zacks research report on Endo International (ENDP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Endo International (NASDAQ:ENDP)

Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.